InfraReDx Inc. closed a $24.1 million equity funding round boosted by 42 existing shareholders.
The Burlington, Mass.-based company develops the LipiScan IVUS device, which employs both so-called “near-infrared” (NIR) spectroscopy and intravascular ultrasound (IVUS) technology to give cardiologists a grayscale image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.
The data enables cardiologists to both visualize coronary plaques to guide stent placement and determine whether the build-ups are comprised of the fatty plaques that complicate stenting procedures and patients’ recovery.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company said LipiScan IVUS is the first and only CE Mark approved product to pair NIR spectroscopy and IVUS technology into one system.
Proceeds from the financing will go to expanding manufacturing operations and commercial infrastructure for LipiScan, and to ongoing and new clinical trials investigating expanded clinical applications for the device, according to a company release.
LipiScan won FDA 510(k) clearance in September 2010 and CE Mark approval in European Union in February of this year.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
